Bone Metastasis
Market Research Report, by Type (Osteolytic, Osteoblastic, Mixed), Diagnosis
(Biopsy, Blood Test, Imaging), Treatment (Medical Therapies, Surgery,
Medication), End User (Hospital, Diagnostic Centers) - Global Forecast Till
2023
Market Highlights
The global Bone Metastasis Market is expected to grow at an approximate CAGR of 8.4%
during the forecast period The increasing prevalence of breast cancer, growing
geriatric population, rising healthcare expenditures, and increasing R&D
expenses by the key players are estimated to drive the market growth during the
forecast period. However, factors such as lack of healthcare services in
low-income countries, the high cost of treatment, and related side effects are
estimated to restrain the market growth during the forecast period.
Segmentation
The global Bone Metastasis Market
is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market
is segmented into osteolytic bone metastasis, osteoblastic bone metastasis,
mixed bone metastasis, and others. On the basis of diagnosis, the market is
categorized into biopsy, blood test, imaging, and others. The imaging segment
is sub-segmented into X-ray, bone scintigraphy, computerized tomography,
magnetic resonance imaging, positron emission tomography, and others. On the
basis of treatment, the market is segmented into medical therapies, surgery,
medication, and others. The medical therapies segment is sub-segmented into
chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others.
The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and
others. The medication segment is sub-segmented into pain medications, bone
building medications, and others. On the basis of end-user, the market is
segmented into hospitals and clinics, diagnostic centers, pharmacies, and
ambulatory surgical centers.
Regional Analysis
America dominates the global Bone
Metastasis Market owing to the presence of a well-developed healthcare sector,
increasing prevalence of breast cancer, and rising healthcare sector within the
region. Europe stands second in the market and is followed by Asia Pacific
owing to the availability of funds for research and a huge patient population.
Europe is segmented into Western Europe and Eastern Europe. Western Europe
leads the regional market due to the presence of developed economies such as
Italy, Germany, France, and others within the region. Asia Pacific is projected
to be the fastest growing region in the global Bone Metastasis Market. The
presence of a developing healthcare sector and increasing prevalence of cancer
are expected to be the major drivers for the market growth during the forecast
period. The Middle East and Africa holds the least share in the market. This
can be attributed to the presence of poor economies, stringent government
policies, and lack of healthcare services, especially within the African
region.
Key Players
The key players in the global
Bone Metastasis Market are F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG (Germany), Merck &
Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence
Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC
(U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.
No comments:
Post a Comment